|Over a week ago|
ClearPoint Neuro announces Ellisa Cholapranee as General Counsel » 16:2803/2403/24/21
ClearPoint Neuro announced that Ellisa Cholapranee will join the Company as General Counsel on April 5. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "Ellisa is a tremendous addition to our capable and growing leadership team," commented Joe Burnett, President and CEO of ClearPoint Neuro. "Not only does Ellisa offer the broad experience in compliance, contracting and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight having worked extensively as a partner to the pharma industry will enhance communication and efficiency, both in signing new gene therapy and stem cell partners, as well as broaching more sophisticated risk sharing agreements with our collaborators."
Lake Street starts ClearPoint Neuro at Buy, sees 'billion-dollar' cap potential » 09:0403/1803/18/21
As previously reported,…
As previously reported, Lake Street analyst Frank Takkinen initiated coverage of ClearPoint Neuro with a Buy rating and $32 price target. The company has "established a safer, more precise navigational tool" and its platform technology enables real-time, MRI-guided, minimally-invasive neurosurgery, Takkinen tells investors. He sees markets and products "supporting ClearPoint as a billion-dollar market cap company," the analyst added.
ClearPoint Neuro initiated with a Buy at Lake Street » 08:3903/1803/18/21
Lake Street analyst Frank…
Lake Street analyst Frank Takkinen initiated coverage of ClearPoint Neuro with a Buy rating and $32 price target.
Eight new option listings and one option delisting on March 15th » 08:3003/1503/15/21
AEVA, CLPT, DSSI, GTYH, IEC, INMB, LUNA, POSH, IPV
New option listings for…
New option listings for March 15th include Aeva Technologies Inc (AEVA), ClearPoint Neuro Inc (CLPT), Diamond S Shipping Inc (DSSI), GTY Technology (Class A) (GTYH), IEC Electronics (IEC), INmune Bio Inc (INMB), Luna Innovations (LUNA), and Poshmark Inc (Class A Stock) (POSH). Option delistings effective March 15th include InterPrivate Acquisition Corp (IPV).
|Over a month ago|
ClearPoint Neuro price target raised to $38 from $23 at B. Riley Securities » 08:2102/2202/22/21
B. Riley Securities…
B. Riley Securities analyst Andrew D'Silva raised the firm's price target on ClearPoint Neuro to $38 from $23 and reiterates a Buy rating on the shares. The joint development agreement with Blackrock Microsystems and license and research agreement with Philips position ClearPoint to "expedite various growth initiatives and materially expand" its total addressable market, D'Silva tells investors in a research note.
Fly Intel: Pre-market Movers » 08:5802/1902/19/21
JFU, FUTU, TIGR, WATT, KLR, DE, PTE, MGA, KIRK, MITT, ROKU, RXT, DBX, ASPN, CLPT, TWLO, AAPL
Check out this morning's…
ClearPoint Neuro 1.85M share Spot Secondary priced at $23.50 » 06:0902/1902/19/21
B. Riley Securities acted…
B. Riley Securities acted as lead book running manager for the offering.
ClearPoint Neuro, Philips enter license and research agreement for Maestro » 16:4302/1802/18/21
ClearPoint Neuro (CLPT)…
ClearPoint Neuro (CLPT) announced a worldwide license and research agreement with Philips (PHG), to commercialize the ClearPoint 'Maestro' Brain Model. The company expects the first-generation anatomical segment analysis tool to be launched in 2022.
ClearPoint Neuro announces common stock offering, no amount given » 16:3702/1802/18/21
ClearPoint Neuro announced the commencement of a proposed underwritten public offering of its shares of common stock. All the shares will be offered by the company. B. Riley Securities is acting as book-running manager and Lake Street Capital Markets is acting as co-manager for the proposed offering.
ClearPoint, Blackrock Microsystems in development pact with option agreement » 16:3802/1102/11/21
ClearPoint Neurony announced a multi-product joint development and option agreement with Blackrock Microsystems . Blackrock is a technology leader in the neuroscience, neural engineering, and neural prosthetics space, and specializesom spinal cord injuries, neurological disorders and amyotrophic lateral sclerosis or ALS. "We are thrilled to announce this partnership with Blackrock and enter several existing Neurosurgery markets, representing an estimated combined addressable market of over $100 million, with differentiated and innovative products," commente in implantable electrode arrays, most notably the Utah Array, capable of measuring individual neuronal activity. Blackrock electrodes are used in brain-computer-interfaces to restore function for patients suffering frd Joe Burnett, President and CEO of ClearPoint Neuro. "We believe that Blackrock's expertise in making the most precise neuro-electrodes on the market combined with ClearPoint's strengths in navigation, delivery and case support gives us a clear entry point and path to leadership in established global markets. We expect initial product launches in 2023, starting with the Microelectric Recordingplatform and to be followed with offerings including "smart" biopsy needles and other implantable neural electrodes. MER will allow us to expand beyond the MRI suite and into the Operating Room where more than 90% of deep brain stimulation procedures are performed today. ClearPoint's goal is to supply a portfolio of products for both the MRI and the OR, allowing surgeons to decide which arena they feel is more appropriate for each individual patient presentation."